ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2022
Application of an iPSC-Derived Organoid Model for Localized Scleroderma Therapy.
Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed.
- Hyperbranched Biorefinery Molecule-Regulated Switchable Adhesion and Noninvasive Healing.Small (Weinheim an der Bergstrasse, Germany) · 2026Article
- [Research advances on the application of skin appendage organoids in wound repair].Zhonghua shao shang yu chuang mian xiu fu za zhi · 2026Review
- [Skin organoids: an emerging platform from three-dimensional construction to regenerative application].Zhonghua shao shang yu chuang mian xiu fu za zhi · 2026Review
- Dermal Microvascular Responses of Human Induced Pluripotent Stem Cell-Derived Skin Organoids to Inflammation and Injury.The American journal of pathology · 2026Article
- Innovations in skin microphysiological systems for nonclinical testing and FDA modernization.Microsystems & nanoengineering · 2026Review
- Defining the marker and developmental trajectory of myeloid-derived suppressor cells in aging by single-cell transcriptomics.npj aging · 2025Article
- Organoids for tissue repair and regeneration.Materials today. Bio · 2025Review
- Recent progress in the identification and in vitro culture of skin organoids.Regenerative therapy · 2025Review
- Review
- Skin organoid transplantation promotes tissue repair with scarless in frostbite.Protein & cell · 2025Article
- Functional regeneration strategies of hair follicles: advances and challenges.Stem cell research & therapy · 2025Review
- Organoids in skin wound healing.Burns & trauma · 2025Review
- Advances in engineered organoid models of skin for biomedical research.Burns & trauma · 2025Review
- 3-D bioprinted human-derived skin organoids accelerate full-thickness skin defects repair.Bioactive materials · 2024Article
- Efficient Generation of Skin Organoids from Pluripotent Cells via Defined Extracellular Matrix Cues and Morphogen Gradients in a Spindle-Shaped Microfluidic Device.Advanced healthcare materials · 2024Article
- Human-Induced Pluripotent Stem Cells in Plastic and Reconstructive Surgery.International journal of molecular sciences · 2024Review
- Advancing Organoid Engineering for Tissue Regeneration and Biofunctional Reconstruction.Biomaterials research · 2024Review
- Organoids: new frontiers in tumor immune microenvironment research.Frontiers in immunology · 2024Review
- Bioengineered skin organoids: from development to applications.Military Medical Research · 2023Review
- A Review of Advanced Biomaterials and Cells for the Production of Bone Organoid.Small science · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
Abstract
Localized scleroderma (LoS) is a rare chronic disease with extensive tissue fibrosis, inflammatory infiltration, microvascular alterations, and epidermal appendage lesions. However, a deeper understanding of the pathogenesis and treatment strategies of LoS is currently limited. In the present work, a proteome map of LoS skin is established, and the pathological features of LoS skin are characterized. Most importantly, a human-induced pluripotent stem cell-derived epithelial and mesenchymal (EM) organoids model in a 3D culture system for LoS therapy is established. According to the findings, the application of EM organoids on scleroderma skin can significantly reduce the degree of skin fibrosis. In particular, EM organoids enhance the activity of epidermal stem cells in the LoS skin and promotes the regeneration of sweat glands and blood vessels. These results highlight the potential application of organoids for promoting the recovery of scleroderma associated phenotypes and skin-associated functions. Furthermore, it can provide a new therapeutic alternative for patients suffering from disfigurement and skin function defects caused by LoS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.